{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:35:05Z","timestamp":1781267705517,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jns.2024.123096","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T18:19:22Z","timestamp":1718475562000},"page":"123096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["An open-label pilot study of losmapimod to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments in participants with facioscapulohumeral muscular dystrophy type 1"],"prefix":"10.1016","volume":"462","author":[{"given":"Joost","family":"Kools","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol","family":"Voermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mitelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Mellion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekananda","family":"Ramana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baziel G.M.","family":"van Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jns.2024.123096_bb0005","first-page":"1916","article-title":"Facioscapulohumeral muscular dystrophy","volume":"22","author":"Statland","year":"2016","journal-title":"Continuum (Minneap. Minn.)"},{"key":"10.1016\/j.jns.2024.123096_bb0010","series-title":"Prevalence and Incidence of Rare Diseases: Bibliographic Data","first-page":"95","author":"Orphanet","year":"2022"},{"issue":"3","key":"10.1016\/j.jns.2024.123096_bb0015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ncl.2014.04.003","article-title":"Facioscapulohumeral muscular dystrophy","volume":"32","author":"Statland","year":"2014","journal-title":"Neurol. Clin."},{"issue":"6\u20137","key":"10.1016\/j.jns.2024.123096_bb0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0960-8966(01)00201-2","article-title":"Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy","volume":"11","author":"Flanigan","year":"2001","journal-title":"Neuromuscul. Disord."},{"issue":"12","key":"10.1016\/j.jns.2024.123096_bb0025","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2024.123096_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mus.20522","article-title":"Facioscapulohumeral muscular dystrophy","volume":"34","author":"Tawil","year":"2006","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.jns.2024.123096_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.5004","article-title":"Facioscapulohumeral muscular dystrophy-a tale of heterogeneity and the power of clinical assessments","volume":"3","author":"Nguyen","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"3\u20134","key":"10.1016\/j.jns.2024.123096_bb0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000369343","article-title":"Prevalence of muscular dystrophies: a systematic literature review","volume":"43","author":"Theadom","year":"2014","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1016\/j.jns.2024.123096_bb0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/practneurol-2015-001353","article-title":"What\u2019s in a name? The clinical features of facioscapulohumeral muscular dystrophy","volume":"16","author":"Mul","year":"2016","journal-title":"Pract. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123096_bb0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molmed.2020.09.008","article-title":"Therapeutic approaches in facioscapulohumeral muscular dystrophy","volume":"27","author":"Cohen","year":"2021","journal-title":"Trends Mol. Med."},{"issue":"8","key":"10.1016\/j.jns.2024.123096_bb0055","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.57.8.1434","article-title":"Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy","volume":"57","author":"Kissel","year":"2001","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2024.123096_bb0060","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A phase I\/IItrial of MYO-029 in adult subjects with muscular dystrophy","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123096_bb0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.119.259663","article-title":"Clinically advanced p38 inhibitors suppress DUX4 expression in cellular and animal models of facioscapulohumeral muscular dystrophy","volume":"370","author":"Oliva","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.jns.2024.123096_bb0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.119.264689","article-title":"p38\u03b1 regulates expression of DUX4 in a model of facioscapulohumeral muscular dystrophy","volume":"374","author":"Rojas","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.jns.2024.123096_bb0075","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.149915","article-title":"p38 MAPKs - roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets","volume":"6","author":"Brennan","year":"2021","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.jns.2024.123096_bb0080","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","article-title":"Diversity and versatility of p38 kinase signalling in health and disease","volume":"22","author":"Canovas","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.jns.2024.123096_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194197","article-title":"The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: a randomised double-blind placebo-controlled trial","volume":"13","author":"Fisk","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2024.123096_bb0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.rmed.2017.07.002","article-title":"Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD","volume":"130","author":"Pascoe","year":"2017","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.jns.2024.123096_bb0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40262-012-0025-6","article-title":"Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases","volume":"52","author":"Yang","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.jns.2024.123096_bb0100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CRD.0000000000000176","article-title":"Effects of anti-inflammatory medications in patients with coronary artery disease: a focus on losmapimod","volume":"26","author":"Tun","year":"2018","journal-title":"Cardiol. Rev."},{"issue":"15","key":"10.1016\/j.jns.2024.123096_bb0105","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.2016.3609","article-title":"Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial","volume":"315","author":"O\u2019Donoghue","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2024.123096_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2019.06.073","article-title":"Safety and tolerability of losmapimod, a selective p38\u03b1\/\u03b2 MAPK inhibitor, for treatment of FSHD at its root cause","volume":"29","author":"Cadavid","year":"2019","journal-title":"Neuromuscul. Disord."},{"issue":"1","key":"10.1016\/j.jns.2024.123096_bb0115","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12964-023-01337-4","article-title":"p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics","volume":"21","author":"Ahmadi","year":"2023","journal-title":"Cell Commun. Signal"},{"issue":"12","key":"10.1016\/j.jns.2024.123096_bb0120","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1111\/bcp.14884","article-title":"Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: safety, tolerability, pharmacokinetics, and target engagement","volume":"87","author":"Mellion","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2024.123096_bb0125","article-title":"Results from 96 weeks open-label extension of a phase 2 trial of losmapimod in subjects with FSHD: ReDUX4","author":"Wang","year":"2023","journal-title":"MDA Clin. Sci. Conf."},{"issue":"5","key":"10.1016\/j.jns.2024.123096_bb0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1474-4422(24)00073-5","article-title":"Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"23","author":"Tawil","year":"2024","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123096_bb0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/mus.23911","article-title":"Longitudinal features of STIR bright signal in FSHD","volume":"49","author":"Friedman","year":"2014","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2024.123096_bb0140","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/mus.24287","article-title":"Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by Kinect","volume":"51","author":"Han","year":"2015","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.jns.2024.123096_bb0145","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","article-title":"A motor function measure for neuromuscular diseases. Construction and validation study","volume":"15","author":"Berard","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jns.2024.123096_bb0150","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/j.rehab.2016.07.195","article-title":"The Motor Function Measure (MFM) in the Facio Scapulo Humeral Dystrophy (FSHD) Population: Description and Responsiveness","volume":"59","author":"Lattre","year":"2016","journal-title":"Ann. Phys. Rehabil. Med."},{"issue":"2","key":"10.1016\/j.jns.2024.123096_bb0155","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J. Am. Geriatr. Soc."},{"issue":"3","key":"10.1016\/j.jns.2024.123096_bb0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jns.2024.123096_bb0165","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/mus.27951","article-title":"The Facioscapulohumeral Muscular Dystrophy-Health Index: development and evaluation of a disease-specific outcome measure","volume":"68","author":"Varma","year":"2023","journal-title":"Muscle Nerve."},{"issue":"12","key":"10.1016\/j.jns.2024.123096_bb0170","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008123","article-title":"Patient-reported symptoms in facioscapulohumeral muscular dystrophy (PRISM-FSHD)","volume":"93","author":"Hamel","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2024.123096_bb0175","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1111\/ene.14863","article-title":"The facioscapulohumeral muscular dystrophy Rasch-built overall disability scale (FSHD-RODS)","volume":"28","author":"Mul","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123096_bb0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/bcp.12063","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers","volume":"76","author":"Barbour","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.jns.2024.123096_bb0185","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/CIRCULATIONAHA.110.971986","article-title":"Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia","volume":"123","author":"Cheriyan","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2024.123096_bb0190","series-title":"Losmapimod Reduces DUX4 Expression Across Genotypes in FSHD Patient-Derived Myotubes","author":"Rojas","year":"2019"},{"key":"10.1016\/j.jns.2024.123096_bb0195","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3389\/fphar.2019.00625","article-title":"Losmapimod protected epileptic rats from hippocampal neuron damage through inhibition of the MAPK pathway","volume":"10","author":"Li","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jns.2024.123096_bb0200","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2012.01647.x","article-title":"DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?","volume":"17","author":"Tassin","year":"2013","journal-title":"J. Cell. Mol. Med."},{"issue":"5","key":"10.1016\/j.jns.2024.123096_bb0205","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.nmd.2023.04.001","article-title":"Assessment of the burden of outpatient clinic and MRI-guided needle muscle biopsies as reported by patients with facioscapulohumeral muscular dystrophy","volume":"33","author":"Kools","year":"2023","journal-title":"Neuromuscul. Disord."},{"issue":"3","key":"10.1016\/j.jns.2024.123096_bb0210","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF00705091","article-title":"Assessment of skeletal muscle damage in successive biopsies from strength-trained and untrained men and women","volume":"65","author":"Staron","year":"1992","journal-title":"Eur. J. Appl. Physiol. Occup. Physiol."},{"issue":"4","key":"10.1016\/j.jns.2024.123096_bb0215","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ajpath.2012.07.007","article-title":"Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD","volume":"181","author":"Krom","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jns.2024.123096_bb0220","series-title":"Evaluating DUX4 activity in a phase 2, randomized, double-blind, placebo-controlled, 48-week study of the efficacy and safety of losmapimod in subjects with FSHD","first-page":"P724","author":"Tawil","year":"2021"},{"key":"10.1016\/j.jns.2024.123096_bb0225","series-title":"Characterizing Microenvironmental Changes to Effectively Treat Muscle Dysfunction","author":"Raman","year":"2021"},{"key":"10.1016\/j.jns.2024.123096_bb0230","article-title":"Losmapimod shows significant effect on facioscapulohumeral muscular dystrophy despite unchanged biomarkers","author":"Meglio","year":"2022","journal-title":"Neurol. Live"},{"issue":"3","key":"10.1016\/j.jns.2024.123096_bb0235","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/JND-180318","article-title":"MRI-guided biopsy as a tool for diagnosis and research of muscle disorders","volume":"5","author":"Lassche","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"issue":"4","key":"10.1016\/j.jns.2024.123096_bb0240","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/mus.23949","article-title":"Risk of functional impairment in Facioscapulohumeral muscular dystrophy","volume":"49","author":"Statland","year":"2014","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.jns.2024.123096_bb0245","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nmd.2019.05.006","article-title":"Longitudinal study of upper extremity reachable workspace in fascioscapulohumeral muscular dystrophy","volume":"29","author":"Hatch","year":"2019","journal-title":"Neuromuscul. Disord."},{"issue":"1","key":"10.1016\/j.jns.2024.123096_bb0250","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12891-021-04134-7","article-title":"Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy","volume":"22","author":"Wang","year":"2021","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.jns.2024.123096_bb0255","unstructured":"Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH). ClinicalTrials.gov [Internet], National Library of Medicine (US), Bethesda (MD), 2023 2000 Feb 29 -. Identifier NCT05397470, Facioscapulohumeral Dystrophy (FSHD) [cited 2023 Jul 19]; Available from:. https:\/\/clinicaltrials.gov\/study\/NCT05397470?cond=FSHD&rank=2."},{"issue":"4","key":"10.1016\/j.jns.2024.123096_bb0260","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.nmd.2013.01.008","article-title":"Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy","volume":"23","author":"Statland","year":"2013","journal-title":"Neuromuscul. Disord."},{"issue":"6","key":"10.1016\/j.jns.2024.123096_bb0265","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/1531-8249(199906)45:6<751::AID-ANA9>3.0.CO;2-M","article-title":"Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype","volume":"45","author":"Ricci","year":"1999","journal-title":"Ann. Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:29:35Z","timestamp":1777422575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24002314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":53,"alternative-id":["S0022510X24002314"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123096","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label pilot study of losmapimod to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments in participants with facioscapulohumeral muscular dystrophy type 1","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123096"}}